By Lori Bamber, Managing Editor
In September, Danish-based pharmaceutical company Novo Nordisk collaborated with the Royal Danish Consulate General and the Canadian Diabetes Association to host Innovation in Diabetes Care: 90 Years and Beyond.
Held at the MaRS Discovery District, the event celebrated Novo Nordisk Canada’s 30-year anniversary and the significant contribution Canada has made to diabetes care.
Guests learned more about the findings of the Novo Nordisk-sponsored DAWN2 study, an international initiative that highlights new opportunities for improving active engagement, education and support of people with diabetes and their families.
“The key to a better future for people living with diabetes is to foster these collaborations and, together, continue to drive innovation and education,” said Novo Nordisk president Vince Lamanna.
The DAWN2™ study highlights new opportunities for improving active engagement, education and psychosocial support of people with diabetes and their families.
This global partnership initiative led by Novo Nordisk provides a new platform for dialogue and action to improve the lives of people with diabetes.
The ‘Rule of Halves’
• Of the estimated 382 million people with diabetes...
• about 50% are diagnosed...
• of whom about 50% receive care...
• of whom about 50% achieve treatment targets...
• of whom about 50% achieve desired outcomes.
Only 6% of people with diabetes live a life free
from diabetes-related complications
Click for full report SpecialFeature.diabetes.ca